INTRODUCTION
Atypical carcinoids (ACs) of the lung are rare intermediate-grade neoplasms which are part of a wide spectrum of neuroendocrine tumours ranging from the typical carcinoid to small cell lung carcinoma. Although this type of neoplasm can be found throughout the body, the bronchial tree is the most frequent location for approximately 25% of carcinoid tumours. 1 In 1998, Arrigoni's 2 long-standing histological criteria for the diagnosis of AC ( presence of five or more mitoses in 2 mm 2 or focal necrosis) 2 were modified by Travis and colleagues and then accepted by WHO and the International Association for the Study of Lung Cancer (IASLC) in 1999. Atypical carcinoid was thence defined as a tumour with neuroendocrine morphology and mitotic counts of two or more and less than 10 per 2 mm 2 of viable tumour (10 high-power fields), or the presence of punctate foci of coagulative necrosis. 3 Large areas of geographic necrosis typical of high-grade neuroendocrine carcinomas are not seen. 4 Although the aggressive behaviour of AC is well known, factors predisposing to poor prognosis are uncertain. Regional disease with spread to local lymph nodes occurs frequently in AC tumours. Published studies related a variable rate of lymph node disease of anywhere from 20% to 60% of cases. [5] [6] [7] Nevertheless, the main prognostic factors in these neoplasms are undefined in the literature. We present our experience in this kind of neuroendocrine tumours.
MATERIAL AND METHODS
The Spanish Multicenter Study of Neuroendocrine Tumours of the Lung (EMETNE is the Spanish acronym) is a cooperative multicenter group composed of 26 hospitals throughout Spain. All resected neuroendocrine lung tumours at any of the participating institutions from 1980 were registered and classified into one of the following categories: typical carcinoid, AC, large cell neuroendocrine carcinoma (LCNEC), and small cell lung carcinoma. We collected 127 AC tumours that were operated between 1980 and 2009. Before 1998, cases were retrieved retrospectively. From 1998, new cases were collected in a prospective manner. Local lung pathologists reviewed all samples to classify them following the 1999 WHO classification, including Travis's new criteria for AC. Patients underwent complete surgical resection of the tumour in all cases. From 1980 to 1997, a mediastinal lymph node sampling was associated. In the prospective group, systematic nodal dissection was carried out.
We studied clinical behaviour in these tumours, analysing prognostic significance and patterns of nodal affection and recurrence. Clinical variables considered were: age, gender, location of the tumour, size, surgical procedure and nodal status using the tumour-node-metastasis (TNM) classification. 8 Histological feature variables were: tumour differentiation, tumour pattern, angio-lymphatic invasion and immunohistochemical markers (chromogranin, synaptophysin and neuronspecific enolase in all cases). The resection extent was also studied, dividing the series into lobar resections (LR) (lobectomy, bi-lobectomy and pneumonectomy) and sublobar resections (SR) (segmentectomy and isolated bronchial resection), as well as adjuvant treatment (chemotherapy (ChT), and radiotherapy (RT)). Survival analysis data were collected from a systematic follow-up database. Local recurrence and distant metastasis were also assessed.
Statistical analysis was carried out using a SPSS V.19.0 statistical package programme. Categorical variables were compared using χ 2 test. Mean differences were assessed using t test or analysis of variance. Cumulative survival probabilities were estimated by the Kaplan-Meier test. A multivariable analysis was performed in order to determine prognostic factors using linear regression or Cox's regression. A p value of <0.05 was considered significant. Multimodal therapy after surgery was indicated in an individualised manner. Eighteen patients underwent any kind of adjuvant treatment (11 ChT, . Four patients of this group were N0 (3 ChT because of the size of the tumour (larger than 7 cm, cT3) and 1 RT because of sublobar resection). Fourteen of these patients were classified as N+.
RESULTS

From
Thirty-two out of 127 patients (25.2%) presented some kind of recurrence during the outcome: 5 corresponded to locoregional recurrences (3.9%), 22 were distant metastasis (17.3%) and 5 patients had both types (3.9%). The most prevalent location for locoregional recurrence was mediastinal lymph nodes, while the liver was the most typical location for distant metastasis.
Twenty-three patients died during monitoring, 12 because of the tumour and 11 from other causes (not attributable to tumour progression). Median survival for death from any cause in the AC follow-up was 47 months. Five-year overall survival rate in AC was 80%. None of the pathological tumour characteristics (differentiation grade, tumour pattern, bone metaplasia and immunohistochemical markers) were found to be significant for survival influence. In a univariable analysis, T-status categories presented statistical signification related to survival of these patients ( p=0.005). As to the prognostic significance of nodal disease in survival of patients affected by AC, 5-year survival for N0, N1 and N2 cases was 88%, 68% and 64%, respectively. We discarded the only N3 case for prognostic analysis. When we compared N0 survival with N+ survival in these patients, differences observed were statistically significant ( p=0.021) (figure 1). In the N+ patients, there were no statistical differences in survival or recurrence between patients receiving or not receiving adjuvant treatment. Six patients presented solitary M1 disease at the time of lung surgery (metastatic tumour was previously curatively treated). These M1 patients had a significantly worse survival prognosis than the M0 (estimated mean survival time 171.3 months in M0 group vs 73.7 months in M1 group; p=0.040) (table 4) . Recurrence also affected survival adversely. When we studied the prognostic behaviour of patients presenting locoregional recurrence, we found clinical differences. Estimated mean survival time for locoregional recurrence was 90.4 months (95% CI 63.2 to 117.6), against 169.4 months for patients without locoregional recurrence (95% CI 150.8 to 188.0). However, this difference was not statistically significant ( p=0.435). Patients who developed distant metastasis during follow-up presented significantly poorer survival than those who did not (p<0.001) (figure 2), presenting a 5-year survival rate of 39%. Median survival time for distant disease, locoregional disease and recurrence-free patients was 38, 114 and 180 months, respectively. In a multivariable analysis, the development of distant recurrence was demonstrated as the main independent risk factor for survival of these patients ( p<0.001; HR=13.095; 95% CI for HR: 5.048 to 33.974).
Recurrence relationship between type of resection practiced and recurrence was assessed. We observed that patients who underwent SR developed locoregional recurrence more frequently (6 patients; 37.5%) than those who received LR (4 patients; 3.9%) ( p<0.001) ( figure 3 ). Ninety-eight percent of patients who underwent LR were free of locoregional recurrence 2 years after surgery (71% for the SR group).
When analysing distant recurrence, tumour size according to TNM system cut-off presented clinical differences in this aspect, but without statistical significance ( p=0.550), possibly due to sample size. With respect to distant recurrence, T-status did present statistical differences related to the time to metastasis in the univariable recurrence analysis ( p<0.001) (figure 4).
Another important topic is the relationship between nodal invasion and recurrence. We observed that the higher the N-status of the patient, the higher the frequency of distant metastasis (16.7%, 27.8% and 33.4% for N0, N1 and N2, respectively). For locoregional recurrence, differences were not so important, perhaps because of the few cases collected for this group (7.1%, 5.5% and 8.3% for each step of N-status).
Although we could not demonstrate statistical signification for these clinical differences ( p=0.961 for locoregional recurrence and p=0.154 for distant metastasis), we found significant differences between N0 and N+ patients when considering any kind of recurrence (locoregional and/or distant) ( p=0.019) (figure 5). In fact, when we analysed the frequency of locoregional recurrence between the LR group and the SR, stratifying data by N-status, we could confirm statistical differences (p<0.001). The estimated mean for time to locoregional recurrence in N0 patients was 204.33 months (95% CI 187.92 to 220.74) for the Figure 1 Prognostic influence of N-status in atypical carcinoid. Univariable analysis (Kaplan-Meier) ( p=0.049). In a multivariable analysis, SR was considered as an independent prognostic factor to predict locoregional recurrence in these patients ( p=0.002; HR=18.111; 95% CI for HR: 2.893 to 113.362).
Finally, the prognostic effect of adjuvant ChT was analysed. Patients who underwent adjuvant ChT did not present any statistical differences regarding survival and recurrence ( p=0.327 and p=0.294, respectively) (table 4). At any rate, adjuvant treatment was infrequent and varied considerably, so it is difficult to arrive at any further conclusions.
COMMENT
Atypical carcinoid represents an infrequent lung neoplasm, included in the neuroendocrine spectrum and defined by Travis' 3 modified histological criteria. The criteria for diagnosis of AC includes the existence of 2-10 mitoses per 2 mm 2 area, or the presence of small punctuate foci of necrosis. Additionally, nucleoli can be seen in AC. 9 Recently, the seventh edition of the Union for International Cancer Control/American Joint Committee on Cancer TNM system has been recommended for the classification of pulmonary carcinoid tumours. 8 Frequency ranges for AC reported in the literature vary from 14% to 33% of carcinoid tumours, [10] [11] [12] [13] which is consistent with our data. Almost one-third of patients remain asymptomatic at the moment of the diagnosis, 14 which agrees with our observations. Accepting these facts, although many AC characteristics are known, the role of prognostic factors is not completely defined.
Intermediate prognosis in AC has been described for many years. Garcia-Yuste and colleagues, 10 Cardillo and colleagues 15 and Filosso and associates 16 reported an improved prognosis of N0 patients compared to N+ cases. Stamatis and colleagues 17 Figure 2 Prognostic influence of distant metastasis during the outcomes. Univariable analysis (Kaplan-Meier) ( p<0.001). reported a high frequency of nodal hilar and mediastinal metastases in AC, but they did not indicate any prognostic factors for this kind of neuroendocrine neoplasms. Thomas and associates 12 found AC histology to be an important prognostic factor related to survival of patients with carcinoid tumours. Many other authors agree with this observation. 18 19 However, the authors did not describe specific prognostic factors for AC. Although tumour size and recurrences are related to life expectancy, in our experience, nodal disease remains an important prognostic factor to predict survival and recurrence.
Nodal disease is a frequent feature in AC. In fact, its relationship with prognosis has been reported in these patients. 20 The investigation for lymph node metastases seems to be an unavoidable requisite to establish prognosis and to evaluate therapeutic strategies.
11 Invasive mediastinal staging with mediastinoscopy inspection has been recommended for cN1 and cN2 tumours.
14 Our data support this statement, because of the poorer prognosis of patients with nodal involvement as well as the higher frequencies of recurrences in this group. This supports the requirement of an appropriate and reliable mediastinal staging (endobronchial or transesophageal endoscopic ultrasoundguided needle aspiration biopsy, mediastinoscopy or thoracoscopy) before surgical treatment.
In the same line as our work, nodal involvement and complete resection were recognised as prognostic predictors in AC during the 2007 International Workshop on Advances in Pulmonary Neuroendocrine Tumours. 21 Intermediate survival for patients with AC was reported, with distal site recurrence being more common than local recurrence. In our experience, nodal affection and recurrence are closely related. Davini and colleagues 13 stated that ACs are more likely to recur regardless of stage, but their data did not support this affirmation. By contrast, Rea and colleagues 11 observed that 50% of recurrences observed in AC were N+. Other authors have noted the relevance of lymph node micrometastasis detected by immunohistochemical techniques, 22 worsening the prognosis of these patients for survival and recurrence. This would support radical lymphadenectomy in these cases. The analysis of our data allows us to demonstrate that a higher N-status influences the probability of tumour recurrence, confirming the need to determine lymph node involvement systematically in these patients.
Surgery represents the cornerstone of treatment of AC tumours. Complete standard surgical resection and mediastinal lymph node dissection is the treatment of choice. Atypical resections have been related to an increased number of recurrences in AC. 23 In our series, 24% of patients who underwent SR presented locoregional recurrence at some time during follow-up. Furthermore, patients who underwent these SRs presented a higher incidence of locoregional recurrence when compared with LR, independently of N-status. This observation could suggest that the magnitude of resection is a predictive variable for locoregional recurrence, not only lymph node invasion. Emphasising this issue, Yendamuri and colleagues 24 have attempted to ascertain whether SRs are sufficient for carcinoid tumours. They have recommended avoiding lobectomies in typical carcinoid tumours, although they find the atypical histology to be an adverse prognostic factor. Nevertheless, they make no indication about AC. In the same direction, Fox and colleagues 25 have recently published the experience of the Surveillance Epidemiology and End Results (SEER) database about this aspect. Even when they do not find any diseasespecific mortality in patients undergoing SR because of AC, the authors make no recommendation regarding these tumours.
Moreover, they could not perform any recurrence analysis because of the lack of information in coding the data from SEER database. Our series, one of the largest published to date, specifically focused on AC, shows that SR should be reserved for patients at high cardiopulmonary risk, based on locoregional recurrence rates. As to surgical indication in cases of M1 preoperatively treated patients, we did not find any recommendations in the literature. In our experience, these patients present lower life expectancy and a higher recurrence rate than those staged as M0.
Focusing on adjuvant treatment of these tumours, there is no consensus about which patients could benefit from multimodal therapy. Some authors have tried to identify potential candidates for adjuvant ChT. Survival of N+ AC patients is poorer than survival in N0 patients. That is the reason why these patients could be candidates for adjuvant therapy. However, there is insufficient evidence to assess the efficacy of this treatment and the agent of choice. 21 Data about this are scarce and inconsistent in our series, so we cannot draw a conclusion on the results obtained in this aspect.
In conclusion, nodal status, extent of resection and recurrence will affect prognostic evolution of these patients. Bearing in mind these data, standard surgical resection with radical lymphadenectomy is essential. In our experience, limited resections should be avoided except for special patient conditions, because of higher recurrence. Further studies with larger sample sizes and new prognostic marker analyses are recommended.
